COVID-19 mRNA Vaccine Targeting Omicron JN.1 Lineage Safe

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 6, 2025.

via HealthDay

WEDNESDAY, Aug. 6, 2025 -- Vaccination with the updated COVID-19 mRNA vaccine containing the severe acute respiratory syndrome coronavirus-2 Omicron JN.1 lineage was not associated with an increased risk for 29 adverse events, according to a study published online July 28 in JAMA Network Open.

Niklas Worm Andersson, M.D., Ph.D., from Statens Serum Institut in Copenhagen, Denmark, and colleagues examined the association between vaccination with JN.1-containing vaccines and the risk for 29 serious adverse events adapted from prioritized lists of adverse events of special interest to COVID-19 vaccines. Outcome rates during the first 28 days after JN.1-containing vaccine administration (i.e., the risk period) were compared to outcome rates during the remaining period.

Participants were adults in Denmark recommended to receive the 2024 to 2025 JN.1-containing booster vaccine who had previously received three or more COVID-19 vaccine doses (1,012,400 individuals). The researchers found that during the 28-day risk period after receipt of a JN.1-containing mRNA vaccine, there were no significant increases in the rate of hospital contacts for any of 29 adverse events compared with reference period rates. The incidence rate ratios were 0.84 (95 percent confidence interval [CI], 0.76 to 0.94), 0.92 (95 percent CI, 0.76 to 1.13), and 1.12 (95 percent CI, 0.41 to 3.10) for ischemic cardiac events, intracranial bleeding, and myocarditis, respectively.

"Although we analyzed a nationwide cohort, some outcomes, such as erythema multiforme, occurred very rarely during follow-up, with consequently lower statistical precision, and some outcomes, such as transverse myelitis, could not be statistically compared," the authors write.

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-07 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords